DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00394589 (ClinicalTrials.gov)	March 2006	31/10/2006	Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)	Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.	Rheumatoid Arthritis	Drug: Infliximab Control;Drug: Infliximab Increased Frequency;Drug: Infliximab Increased Dose	Merck Sharp & Dohme Corp.	Integrated Therapeutics Group	Terminated	18 Years	N/A	All	43	Phase 3	Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

March 2006

31/10/2006

Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.

Rheumatoid Arthritis

Drug: Infliximab Control;Drug: Infliximab Increased Frequency;Drug: Infliximab Increased Dose

Merck Sharp & Dohme Corp.

Integrated Therapeutics Group

Terminated

18 Years

N/A

All

Phase 3

Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey